Skip to content

King Pharmaceuticals KG Investment Purchases

Investment Purchases at other companies

Arch Capital Group logo
Arch Capital GroupACGL
$9.29B-1.4%
Everest Group logo
Everest GroupEG
$2.46B-32.7%
SiriusPoint logo
SiriusPointSPNT
$274.2M-43.7%
Skyward Specialty Insurance Group, Inc. logo
Skyward Specialty Insurance Group, Inc.SKWD
$269.92M+113%
Tiptree Inc. logo
Tiptree Inc.TIPT
KKR & Co. logo
KKR & Co.KKR

Other financials

Income statement

See full
Revenue$10.2M+1,112%
Net income-$7.4M-1,786%
EPS (diluted)-$0.96-586%

Balance sheet

See full
Cash & equivalents$62.2M+1,724%
Total debt$176.7M
Total equity$121.4M+2,773%
Total assets$964.2M

Cash flow

See full
Operating cash flow-$15.1M-1,628%

Valuation

See full
Market cap$70.42M-67.6%
Enterprise value$184.93M-50.0%
P/E1.2×
P/S1.6×-24.3×

Profitability

See full
Net margin131.5%

Returns & leverage

See full
Return on equity90.8%
Debt / equity1.5×

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireOtherInvestments.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's investment purchases.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is King Pharmaceuticals's investment purchases?
King Pharmaceuticals (KG) reported investment purchases of $2.26M in Q1 2026.
What does investment purchases mean?
Cash spent purchasing investment securities across all categories.